
Dr. Jason Mouabbi discusses remaining unmet needs and practical considerations in the management of PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Jason Mouabbi, MD, is an assistant professor of breast medical oncology and general medical oncology at The University of Texas MD Anderson Cancer Center.

Dr. Jason Mouabbi discusses remaining unmet needs and practical considerations in the management of PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi discusses how available pathway-directed treatment approaches may be differentiated for patients with biomarker-selected HR-positive/HER2-negative advanced breast cancer, with consideration of treatment setting and toxicity profiles.

Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back pain after 3 months of treatment.

Dr. Jason Mouabbi discusses how to approach adverse-event attribution when treating patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer with a multidrug regimen.

Dr. Jason Mouabbi discusses additional adverse events that require attention when managing patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer receiving combination therapy.

Dr. Jason Mouabbi revisits the patient's Grade 2 hyperglycemia at week 6, when fasting glucose reaches 212 mg/dL.

Dr. Jason Mouabbi discusses the approach to managing treatment-related hyperglycemia while maintaining cancer treatment for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi reviews the treatment initiation and early glucose monitoring strategy for a patient with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer receiving inavolisib in combination with palbociclib and fulvestrant.

Dr. Jason Mouabbi discusses strategies for assessing and managing the risk of treatment-related hyperglycemia before initiating therapy for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi presents a 59-year-old postmenopausal woman with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer who develops metastatic disease 8 months after completing adjuvant endocrine therapy.

Dr. Jason Mouabbi discusses the role of molecular testing in guiding treatment selection for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi introduces the discussion on managing PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer in clinical practice, with a focus on treatment selection and practical adverse-event management.